American Diverisfied Holdings Corporation (ADHC) to Retain San Diego Based Bio Device Engineering Firm, Arete Bioscience, to Design GlucoGuard's Oral Diabetes Management Device

ADHC Receives Funding Commitment from Small Cap Hedge Fund to Finance GlucoGuard Development

Del Mar, California--(Newsfile Corp. - May 19, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the company is to retain San Diego based bio engineering firm ARETE BIOSCIENCES, Inc. to design the GlucoGuard diabetes device pursuant to the recent FDA Breakthrough Device directive.

Arete BioScience's team of scientists and biomechanical engineers have completed a review of GlucoGuard's foundational documentation including intellectual property, design schematics, and FDA application documentation. The team has devised a development protocol that will be initiated with the input and guidance of GlucoGuard's advisor Dr. Stephen Weber in order to facilitate the next step in the FDA approval process.

Additionally, ADHC has received a funding commitment from a seasoned hedge fund that specializes in financing public companies. This funding will be NON-DILUTIVE following a financing model that is not detrimental to the trading environment of ADHC stock.

This funding will be provided in one or more tranches based upon a "USE OF FUNDS" provided to the hedge fund.

"Developments are rapidly coming to together as development partners are recognizing the potential of the GlucoGuard technology. The GlucoGuard team led by Advisor Dr. Weber, and co Founder Zach Smith are now in a position fully accelerate the development," commented ADHC. "In conjunction with the device engineering, the APP Development in partnership with DEXCOM Continuous Glucose monitoring technology in rapidly progressing," concluded ADHC.

These relationships serve to build out the GlucoGuard footprint as an emerging biodevice technology providing a novel solution to the serious unmet challenge in managing HYPOGLECMIA in diabetic patients.

More news on the DEXCOM partnership progression, how GlucoGuard is utilizing Artificial Intelligence in predicting Hypoglycemia and other key issues will be publicized in the near term.

ABOUT ARETE BIOSCIENCES, Inc.

Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space.